Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart stent showdown: which medicated device keeps arteries open best?

NCT ID NCT07190690

Disease control Sponsor: Fundación EPIC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 6 times

Summary

This study compares two medicated stents (tiny mesh tubes) used to open blocked heart arteries in people having a heart attack or unstable angina. About 2,100 participants will receive either a sirolimus-eluting stent (ihtDEStiny) or an everolimus-eluting stent (Xience). Researchers will track heart-related deaths, heart attacks, and repeat procedures over 12 months to see which stent performs better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Oct 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients who meet ALL inclusion criteria will be included: * Patients aged ≥18 years, and * Patients diagnosed with an acute coronary syndrome (ACS), either SCASEST (Acute Coronary Syndrome without Persistent ST-Segment Elevation) or IAMCEST (Acute Myocardial Infarction with Persistent ST-Segment Elevation), for which they will undergo PCI, and * Patients with de novo lesions in vessels with a reference diameter of ≥2.25 mm and ≤4.5 mm in whom implantation of one or more DES is clinically indicated, and * Patients who have been informed of the characteristics of the study and have provided written informed consent. Exclusion Criteria: Patients must not meet any of the following exclusion criteria: * Patients in cardiogenic shock according to the severity criteria defined by the Society of Cardiovascular Angiography and Interventions (SCAI): "C" (Classic Shock), "D" (Deteriorating) and "E" (Extremis). * Patients unable to provide informed consent. * Patients with a known hypersensitivity or allergy to aspirin or any P2Y12 receptor inhibitor (clopidogrel, prasugrel, ticagrelor), heparin, contrast agents, or any of the components of DES. * Patients with active bleeding at the time of PCI requiring medical attention. * Patients with planned surgery within the next 3 months. * Patients with any medical condition that limits a life expectancy of less than 12 months. * Patients participating in another clinical trial in which the primary endpoint was not met. * Pregnant or breastfeeding women of childbearing potential with a positive pregnancy test.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    20 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Hospital Clínic de Barcelona

    RECRUITING

    Barcelona, 08036, Spain

  • Hospital Clínico Universitario Lozano Blesa

    RECRUITING

    Zaragoza, 50009, Spain

  • Hospital Clínico Universitario de Santiago

    RECRUITING

    Santiago de Compostela, 15706, Spain

  • Hospital General Universitario de Castellon

    RECRUITING

    Castelló, 12004, Spain

  • Hospital Regional Universitario de Málaga

    RECRUITING

    Málaga, 29010, Spain

  • Hospital Universitari Arnau de Vilanova

    RECRUITING

    Lleida, 25198, Spain

  • Hospital Universitari Germans Trias I Pujol

    RECRUITING

    Badalona, 08916, Spain

  • Hospital Universitari Vall d'Hebron

    RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitari de Bellvitge

    RECRUITING

    L'Hospitalet de Llobregat, 08907, Spain

  • Hospital Universitari de Tarragona Joan XXIII

    RECRUITING

    Tarragona, 43005, Spain

  • Hospital Universitario Juan Ramón Jiménez

    RECRUITING

    Huelva, 21005, Spain

  • Hospital Universitario La Paz

    RECRUITING

    Fuencarral-El Pardo, 28046, Spain

  • Hospital Universitario Lucus Agustí

    RECRUITING

    Lugo, 27003, Spain

  • Hospital Universitario Marques de Valdecilla

    RECRUITING

    Santander, 39008, Spain

  • Hospital Universitario San Juan Alicante

    RECRUITING

    Alicante, 03550, Spain

  • Hospital Universitario Virgen de La Arrixaca

    RECRUITING

    El Palmar, 30120, Spain

  • Hospital Universitario de Canarias

    RECRUITING

    San Cristóbal de La Laguna, 38320, Spain

  • Hospital Universitario de Cruces

    RECRUITING

    Barakaldo, 48903, Spain

  • Hospital Universitario de Donostia

    RECRUITING

    Donostia / San Sebastian, 20014, Spain

  • Hospital Universitario de Leon

    RECRUITING

    León, 24008, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.